MindWalk Holdings (HYFT) Capital Expenditures (2023 - 2026)
MindWalk Holdings (HYFT) reported Capital Expenditures of -$22337.7 for Q1 2026, up 71.69% year-over-year from -$13010.7 in Q1 2025, and up 58.13% quarter-over-quarter from -$53345.0 in Q4 2025.
MindWalk Holdings (HYFT) Capital Expenditures (2023 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has 4 years of Capital Expenditures data on file, last reported at -$22337.7 in Q1 2026.
- Capital Expenditures for Q1 2026 came in at -$22337.7, up 71.69% year-over-year; the trailing twelve-month figure through Jan 2026 was $589762.7 (down 35.25% YoY), and the FY2025 annual result was $573592.0, down 44.33% from the prior year.
- Capital Expenditures grew to -$22337.7 in Q1 2026 per HYFT's latest filing, from -$53345.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $1.9 million in Q2 2023 and troughed at -$220510.7 in Q4 2023.
- A 4-year average of $229766.8 and a median of -$53345.0 in 2025 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2024 and 2025: Capital Expenditures soared 167.19% in 2024, then sank 164.64% in 2025.
- A 4-year view of Capital Expenditures shows it stood at -$220510.7 in 2023, then jumped by 78.41% to -$47598.8 in 2024, then declined by 12.07% to -$53345.0 in 2025, then surged by 58.13% to -$22337.7 in 2026.
- Business Quant data shows HYFT's Capital Expenditures at -$22337.7 in Q1 2026, -$53345.0 in Q4 2025, and -$205235.5 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -63,220.27 |
| 10 | MindWalk Holdings | 166.20 Mn | 156.06 Mn | 1.78 | -22,337.66 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -22,337.66 |
| Jan 31, 2026 | -22,337.66 |
| Oct 31, 2025 | -53,345.05 |
| Oct 31, 2025 | -53,345.05 |
| Jul 31, 2025 | -205,235.46 |
| Jul 31, 2025 | -205,235.46 |
| Apr 30, 2025 | 870,680.85 |
| Apr 30, 2025 | 870,680.85 |
| Jan 31, 2025 | -78,895.81 |
| Jan 31, 2025 | -78,895.81 |
| Oct 31, 2024 | -47,598.77 |
| Oct 31, 2024 | -47,598.77 |
| Jul 31, 2024 | -192,072.05 |
| Jul 31, 2024 | -192,072.05 |
| Apr 30, 2024 | 1.23 Mn |
| Apr 30, 2024 | 1.23 Mn |
| Jan 31, 2024 | 122,054.04 |
| Jan 31, 2024 | 122,054.04 |
| Oct 31, 2023 | -220,510.67 |
| Oct 31, 2023 | -220,510.67 |